MicroRNA-221 accelerates the proliferation of laryngeal cancer cell line Hep-2 by suppressing Apaf-1

Sun,Xin; Liu,Bin; Zhao,Xu-Dong; Wang,Li-Yin; Ji,Wen-Yue

doi:10.3892/or.2015.3714

MicroRNA-221 accelerates the proliferation of laryngeal cancer cell line Hep-2 by suppressing Apaf-1

Authors:
- Xin Sun
- Bin Liu
- Xu-Dong Zhao
- Li-Yin Wang
- Wen-Yue Ji
View Affiliations

Affiliations: Department of Otorhinolaryngology, Shengjing Hospital, China Medical University, Heping, Shenyang, Liaoning 110004, P.R. China
Published online on: January 13, 2015 https://doi.org/10.3892/or.2015.3714
Pages: 1221-1226

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Laryngeal cancer is one of the most commonly occurring malignant cancers of the head and neck region. In the present study, we investigated the roles of miR-221 in laryngeal squamous cell carcinoma cell line, Hep-2. We examined the function and mechanism of miR-221 in Hep-2 cells using techniques of cell biology and molecular pathology, such as western blotting, quantitative PCR, immunohistochemical staining and flow cytometry. Using a luciferase assay, the apoptotic protease activating factor-1 (Apaf-1) mRNA 3'-UTR was shown to have complementary binding sites using bioinformatics prediction software including TargetScan, PicTar and miRanda. In conclusion, our results showed that miR-221 inhibition caused elevated expression levels of the Apaf-1 apoptotic pathway proteins caspase-3, -8 and -9. miR-221 may therefore be used as a novel therapeutic target for laryngeal cancer.

View Figures

View References

1	Chen YF, Luo RZ, Li Y, et al: High expression levels of COX-2 and P300 are associated with unfavorable survival in laryngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 270:1009–1017. 2013. View Article : Google Scholar :
2	Chu EA and Kim YJ: Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am. 41:673–695. 2008. View Article : Google Scholar : PubMed/NCBI
3	Chang TC and Mendell JT: microRNAs in vertebrate physiology and human disease. Annu Rev Genomics Hum Genet. 8:215–239. 2007. View Article : Google Scholar : PubMed/NCBI
4	Latronico MV, Catalucci D and Condorelli G: Emerging role of microRNAs in cardiovascular biology. Circ Res. 101:1225–1236. 2007. View Article : Google Scholar : PubMed/NCBI
5	Ergun S, Arman K, Temiz E, et al: Expression patterns of miR-221 and its target caspase-3 in different cancer cell lines. Mol Biol Rep. 41:5877–5881. 2014. View Article : Google Scholar : PubMed/NCBI
6	Ciafrè SA, Galardi S, Mangiola A, et al: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun. 334:1351–1358. 2005. View Article : Google Scholar : PubMed/NCBI
7	Gottardo F, Liu CG, Ferracin M, et al: MicroRNA profiling in kidney and bladder cancers. Urol Oncol. 25:387–392. 2007. View Article : Google Scholar : PubMed/NCBI
8	He H, Jazdzewski K, Li W, et al: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 102:19075–19080. 2005. View Article : Google Scholar : PubMed/NCBI
9	Medina R, Zaidi SK, Liu CG, et al: MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res. 68:2773–2780. 2008. View Article : Google Scholar : PubMed/NCBI
10	le Sage C, Nagel R, Egan DA, et al: Regulation of the p27^Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 26:3699–3708. 2007. View Article : Google Scholar : PubMed/NCBI
11	Gramantieri L, Fornari F, Ferracin M, et al: MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res. 15:5073–5081. 2009. View Article : Google Scholar : PubMed/NCBI
12	Fu X, Wang Q, Chen J, et al: Clinical significance of miR-221 and its inverse correlation with p27^Kip1 in hepatocellular carcinoma. Mol Biol Rep. 38:3029–3035. 2011. View Article : Google Scholar
13	Visone R, Russo L, Pallante P, et al: MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27^Kip1 protein levels and cell cycle. Endocr Relat Cancer. 14:791–798. 2007. View Article : Google Scholar : PubMed/NCBI
14	Gillies JK and Lorimer IA: Regulation of p27^Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle. 6:2005–2009. 2007. View Article : Google Scholar : PubMed/NCBI
15	Ahmed FE, Jeffries CD, Vos PW, et al: Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics. 6:281–295. 2009.PubMed/NCBI
16	Felli N, Fontana L, Pelosi E, et al: MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci USA. 102:18081–18086. 2005. View Article : Google Scholar : PubMed/NCBI
17	Park JK, Kogure T, Nuovo GJ, et al: miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 71:7608–7616. 2011. View Article : Google Scholar : PubMed/NCBI
18	Li P, Nijhawan D, Budihardjo I, et al: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI
19	Lian S, Shi R, Bai T, et al: Anti-miRNA-23a oligonucleotide suppresses glioma cells growth by targeting apoptotic protease-activating factor-1. Curr Pharm Des. 19:6382–6389. 2013. View Article : Google Scholar
20	Zang YS, Zhong YF, Fang Z, et al: MiR-155 inhibits the sensitivity of lung cancer cells to cisplatin via negative regulation of Apaf-1 expression. Cancer Gene Ther. 19:773–778. 2012. View Article : Google Scholar : PubMed/NCBI
21	Paik SS, Jang KS, Song YS, et al: Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype. Ann Surg Oncol. 14:3453–3459. 2007. View Article : Google Scholar : PubMed/NCBI
22	Chen L, Zhang J, Han L, et al: Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status. Oncol Rep. 27:854–860. 2012.